Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY: NVO )

74.18 -3.93 (-5.03%)
Streaming Delayed Price Updated: 10:00 AM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
75 76 Next >
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility. 
Via InvestorPlace
Novo Nordisk Just Hit 3 Snags in a Row. Is Its Stock Still a Buy?
There's reason to believe some of its expected revenue will take longer to arrive. 
Via The Motley Fool
This 1 Piece of Good News for Eli Lilly Is Bad News for Hims & Hers Health Stock
A company's investments can easily ruin the plans of its competitors. 
Via The Motley Fool
Weight Loss Drugs Like Ozempic, Zepbound May Reduce Cancer Risks, Studies Suggest
GLP-1 agonists like Ozempic and Wegovy, known for treating obesity and diabetes, are now showing potential in reducing cancer risk, particularly for cancers linked to obesity. New research highlights... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
NVO Stock Alert: Why Is Novo Nordisk Down 8% Today?
Novo Nordisk stock is down on Wednesday with a Q2 revenue miss as the company disappoints NVO investors despite Wegovy demand increasing. 
Via InvestorPlace
Novo Nordisk Unusual Options Activity For August 06
Via Benzinga
Weight Loss Stocks Could Become Alzheimer's Drugs Stocks. Here's Why That's Bullish for Novo Nordisk
The company's addressable market could eventually be expanded even more. 
Via The Motley Fool
MarketBeat Week in Review – 8/5 - 8/9
Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug
Eli Lilly's Q2 revenue soared to $11.3 billion, surpassing forecasts. Mounjaro sales tripled and Zepbound revenue grew significantly post-FDA approval. Analysts are cautious about future supply and... 
Via Benzinga
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
After Monday's panicked global sell-off, markets have calmed down. 
Via Investor's Business Daily
Novo Nordisk's Shares Go on a Rollercoaster Ride After Earnings
Novo Nordisk fell over 8% after its earnings release but recovered nearly all of those losses the next day. It needs to increase supplies of semaglutide. 
Via MarketBeat
Topics ETFs
Prediction: This Weight Loss Stock Will Be Acquired Within the Next Year
Altimmune is a little-known pharmaceutical company looking to disrupt the weight loss space. 
Via The Motley Fool
It's Too Soon to Buy the Dip in Weight Loss Drugmakers
Obesity drugs are a hot market and one still accelerating as new treatments are approved and usage widens. The bad news is that much of the growth is priced in. 
Via MarketBeat
Novo Nordisk's Growth Opportunities Go Far Beyond Just Weight Loss and Diabetes
Paying a high premium for Novo Nordisk stock may be justifiable based on the company's significant growth opportunities. 
Via The Motley Fool
Here's Why Eli Lilly Stock Dropped 12% Last Month
News from a competitor gave investors an unwelcome dose of reality. 
Via The Motley Fool
Novo Nordisk Withdraws Wegovy FDA Heart Failure Submission, Terminates Development Of Two Early Stage Assets
Novo Nordisk missed Q2 earnings estimates and announced plans to resubmit Wegovy STEP HFpEF trial results for FDA review in early 2025. Despite strong trial data, the FDA requested more extensive... 
Via Benzinga
Exposures Product Safety
Stocks To Watch Today: AXON, LYFT, And Novo Nordisk
Axon Enterprise saw its stock soar nearly 20% on strong AI service demand, while Lyft and Novo Nordisk shares plummeted due to disappointing financial results. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript
NVO earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Shares of Wegovy Maker Novo Nordisk Are Tumbling Today
Investors may have overestimated just how much Ozempic and Wegovy would be selling by now. 
Via The Motley Fool
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
The U.S. 
Via Benzinga
What's Going On With Eli Lilly And Company Shares Wednesday?
Eli Lilly is anticipated to release earnings 2024 fiscal year earnings on Thursday before the market opens. 
Via Benzinga
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
Shares of Novo Nordisk are down 6% after Q2 results fell short of expectations; weight-loss drug sales disappoint. 
Via Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
Via Investor Brand Network
Amgen's MariTide Weight Loss Potential: Stock Outlook
Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Ozempic-Maker Novo Nordisk Reveals Patients Stay On Wegovy Weight-Loss Drug For 6 Months Due To Low Availability
Via Benzinga
Novo Nordisk Slumps On Second-Quarter Miss, Light Ozempic, Wegovy Sales
The company, however, hiked its sales outlook for the year. 
Via Investor's Business Daily
NVO Stock Earnings: Novo Nordisk Misses EPS, Misses Revenue for Q2 2024
NVO stock results show that Novo Nordisk missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Is It Too Late to Buy Novo Nordisk Stock After Its 57% Surge?
Novo Nordisk stock has surged thanks to booming sales of Ozempic and Wegovy. 
Via The Motley Fool
Novo Nordisk Tumbles 3% In Wednesday Premarket: What's Causing 'Miracle' Weight Loss Drug Ozempic Maker's Stock Slide?
The dip in Novo Nordisk's shares comes despite deep-pocketed investors were adopting a bullish approach. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.